ecrin-mdr-crcClinical2018IPD Sharing (as of November 2020): NoUnresectable Metastatic Colorectal CancerColorectal NeoplasmsUnresectable Metastatic Colorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2285775BelgiumUnited States11ECRIN MDRRecruitingfalsealloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cellsThe purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy2018-11-152285775NCT03692429